NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer
B. Salome, J. P. Sfakianos, J. Daza, A. Charap, C. Hammer, R. Banchereau, A. M. Farkas, D. Geanon, G. Kelly, R. M. de Real, B. Lee, K. G. Beaumont, S. Shroff, Y. S. A. Wang, Y.-C. Wang, , Mariath
This study identifies NKG2A and HLA-E as an alternative immune checkpoint axis in bladder cancer, showing NKG2A+ CD8 T cells can bypass HLA-ABC loss through TCR-independent cytotoxicity.
bioRxiv · Mar 4, 2022 · PreprintImmunology